CRISPR Therapeutics AG — Director's Dealing 2020

Jul 9, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2020-07-07

Reporting Person: Novak Rodger (Director, President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-07-07	Common Shares	M	5586	$1.81	Acquired	653593	Direct
2020-07-07	Common Shares	M	19414	$14.00	Acquired	673007	Direct
2020-07-07	Common Shares	S	25000	$90.00	Disposed	648007	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-07-07	Stock Option (Right to Buy)	$1.81	M	5586	Disposed	2025-09-10	Common Shares (5586)	Direct
2020-07-07	Stock Option (Right to Buy)	$14.00	M	19414	Disposed	2026-10-18	Common Shares (19414)	Direct

Footnotes

F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 shares immediately vested on the grant date and the remaining 173,143 shares vesting in 31 equal monthly installments thereafter.

F3: This option was granted on October 18, 2016 with respect to 200,000 Common Shares and originally vested in 48 equal monthly installments beginning October 31, 2016. Pursuant to Dr. Novak's amended and restated employment agreement with the Company, subject to his continued employment, beginning November 30, 2018, the remaining unvested options from this grant vest in equal monthly installments at the rate of 50% of the amounts originally scheduled to vest on any one vesting date, and the original vesting schedule was extended to reflect the amended schedule.